Science 16 February 1990: Vol. 247. no. 4944, pp. 824 - 830 DOI: 10.1126/science.2406902

Prev | Table of Contents | Next

Articles

Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects.

T. Eley, F. R. Luo, S. Agrawal, A. Sanil, J. Manning, T. Li, A. Blackwood-Chirchir, and R. Bertz (2009)
J. Clin. Pharmacol. 49, 700-709
 |  Abstract »  |  Full Text »  |  PDF »

Charting the molecular network of the drug target Bcr-Abl.

M. Brehme, O. Hantschel, J. Colinge, I. Kaupe, M. Planyavsky, T. Kocher, K. Mechtler, K. L. Bennett, and G. Superti-Furga (2009)
PNAS 106, 7414-7419
 |  Abstract »  |  Full Text »  |  PDF »

FIP1L1-PDGFR{alpha} Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells.

K. Fukushima, I. Matsumura, S. Ezoe, M. Tokunaga, M. Yasumi, Y. Satoh, H. Shibayama, H. Tanaka, A. Iwama, and Y. Kanakura (2009)
J. Biol. Chem. 284, 7719-7732
 |  Abstract »  |  Full Text »  |  PDF »

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.

D. H. Kim, W. Xu, C. Ma, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton (2009)
Blood 113, 2517-2525
 |  Abstract »  |  Full Text »  |  PDF »

Glycogen synthase kinase 3{beta} missplicing contributes to leukemia stem cell generation.

A. E. Abrahamsson, I. Geron, J. Gotlib, K.-H. T. Dao, C. F. Barroga, I. G. Newton, F. J. Giles, J. Durocher, R. S. Creusot, M. Karimi, et al. (2009)
PNAS 106, 3925-3929
 |  Abstract »  |  Full Text »  |  PDF »

Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

A. Quintas-Cardama and J. Cortes (2009)
Blood 113, 1619-1630
 |  Abstract »  |  Full Text »  |  PDF »

PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells.

T. Motiwala, S. Majumder, K. Ghoshal, H. Kutay, J. Datta, S. Roy, D. M. Lucas, and S. T. Jacob (2009)
J. Biol. Chem. 284, 455-464
 |  Abstract »  |  Full Text »  |  PDF »

Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia.

D. Bixby and M. Talpaz (2009)
ASCO Educational Book 2009, 395-401
 |  Abstract »  |  Full Text »  |  PDF »

MoKCa database--mutations of kinases in cancer.

C. J. Richardson, Q. Gao, C. Mitsopoulous, M. Zvelebil, L. H. Pearl, and F. M. G. Pearl (2009)
Nucleic Acids Res. 37, D824-D831
 |  Abstract »  |  Full Text »  |  PDF »

Translation of the Philadelphia chromosome into therapy for CML.

B. J. Druker (2008)
Blood 112, 4808-4817
 |  Abstract »  |  Full Text »  |  PDF »

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression.

F.-X. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq, F. Nicolini, C. Belanger, P. W. Manley, C. Leroy, G. Etienne, et al. (2008)
Cancer Res. 68, 9809-9816
 |  Abstract »  |  Full Text »  |  PDF »

Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats.

K. He, M. W. Lago, R. A. Iyer, W.-C. Shyu, W. G. Humphreys, and L. J. Christopher (2008)
Drug Metab. Dispos. 36, 2564-2570
 |  Abstract »  |  Full Text »  |  PDF »

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics).

R. L. Schilsky, G. Gordon, T. M. Gilmer, S. A. Courtneidge, L. M. Matrisian, O. Grad, W. G. Nelson, and on behalf of the Translational Research Working Gr (2008)
Clin. Cancer Res. 14, 5685-5691
 |  Abstract »  |  Full Text »  |  PDF »

Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.

J. Ko, N. Patel, T. Ikawa, H. Kawamoto, O. Frank, R. R. Rivera, R. A. Van Etten, and C. Murre (2008)
PNAS 105, 12967-12972
 |  Abstract »  |  Full Text »  |  PDF »

Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

W. F. Tam, T.-L. Gu, J. Chen, B. H. Lee, L. Bullinger, S. Frohling, A. Wang, S. Monti, T. R. Golub, and D. G. Gilliland (2008)
Blood 112, 1981-1992
 |  Abstract »  |  Full Text »  |  PDF »

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia.

A. Quintas-Cardama and J. Cortes (2008)
Clin. Cancer Res. 14, 4392-4399
 |  Abstract »  |  Full Text »  |  PDF »

Mathematical Models of Cancer Stem Cells.

F. Michor (2008)
J. Clin. Oncol. 26, 2854-2861
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Myeloid Leukemia Stem Cells.

E. Kavalerchik, D. Goff, and C. H.M. Jamieson (2008)
J. Clin. Oncol. 26, 2911-2915
 |  Abstract »  |  Full Text »  |  PDF »

Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.

A. Katsoulas, Z. Rachid, J. P. McNamee, C. Williams, and B. J. Jean-Claude (2008)
Mol. Cancer Ther. 7, 1033-1043
 |  Abstract »  |  Full Text »  |  PDF »

Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway.

N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias (2008)
J. Biol. Chem. 283, 8601-8610
 |  Abstract »  |  Full Text »  |  PDF »

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake (2008)
Blood 111, 2843-2853
 |  Abstract »  |  Full Text »  |  PDF »

Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.

H. Zheng, C. Matte-Martone, H. Li, B. E. Anderson, S. Venketesan, H. Sheng Tan, D. Jain, J. McNiff, and W. D. Shlomchik (2008)
Blood 111, 2476-2484
 |  Abstract »  |  Full Text »  |  PDF »

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.

T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka (2008)
Haematologica 93, 178-185
 |  Abstract »  |  Full Text »  |  PDF »

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment.

A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al. (2008)
Blood 111, 1039-1043
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Myeloid Leukemia Stem Cells.

C. H. Jamieson (2008)
Hematology 2008, 436-442
 |  Abstract »  |  Full Text »  |  PDF »

Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia.

D. White, V. Saunders, A. Grigg, C. Arthur, R. Filshie, M. F. Leahy, K. Lynch, L. B. To, and T. Hughes (2007)
J. Clin. Oncol. 25, 4445-4451
 |  Abstract »  |  Full Text »  |  PDF »

Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

S. J. Neering, T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P.-Y. Wang, D. R. Bell, D. Heinrich, A. Bottaro, and C. T. Jordan (2007)
Blood 110, 2578-2585
 |  Abstract »  |  Full Text »  |  PDF »

Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.

M. Yan, J.-K. Luo, K. J. Ritchie, I. Sakai, K. Takeuchi, R. Ren, and D.-E. Zhang (2007)
Blood 110, 305-312
 |  Abstract »  |  Full Text »  |  PDF »

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

F. Guilhot, J. Apperley, D.-W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, et al. (2007)
Blood 109, 4143-4150
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors.

F. Michor (2007)
Stem Cells 25, 1114-1118
 |  Abstract »  |  Full Text »  |  PDF »

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

J. Cortes, P. Rousselot, D.-W. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, et al. (2007)
Blood 109, 3207-3213
 |  Abstract »  |  Full Text »  |  PDF »

Important Therapeutic Targets in Chronic Myelogenous Leukemia.

H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes (2007)
Clin. Cancer Res. 13, 1089-1097
 |  Abstract »  |  Full Text »  |  PDF »

Why should we still care about oncogenes?.

K. M. Diehl, E. T. Keller, and K. M. Woods Ignatoski (2007)
Mol. Cancer Ther. 6, 418-427
 |  Abstract »  |  Full Text »  |  PDF »

SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.

J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu (2007)
Blood 109, 778-785
 |  Abstract »  |  Full Text »  |  PDF »

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges.

D. A. Thomas (2007)
Hematology 2007, 435-443
 |  Abstract »  |  Full Text »  |  PDF »

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance.

H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes (2006)
Ann Intern Med 145, 913-923
 |  Abstract »  |  Full Text »  |  PDF »

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

B. J. Skaggs, M. E. Gorre, A. Ryvkin, M. R. Burgess, Y. Xie, Y. Han, E. Komisopoulou, L. M. Brown, J. A. Loo, E. M. Landaw, et al. (2006)
PNAS 103, 19466-19471
 |  Abstract »  |  Full Text »  |  PDF »

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure.

F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al. (2006)
Clin. Cancer Res. 12, 7180-7186
 |  Abstract »  |  Full Text »  |  PDF »

Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation..

M. Wetzler, M. T. Brady, E. Tracy, Z.-R. Li, K. A. Donohue, K. L. O'Loughlin, Y. Cheng, A. Mortazavi, A. A. McDonald, P. Kunapuli, et al. (2006)
Clin. Cancer Res. 12, 6817-6825
 |  Abstract »  |  Full Text »  |  PDF »

Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity.

M. A. Meyn III, M. B. Wilson, F. A. Abdi, N. Fahey, A. P. Schiavone, J. Wu, J. M. Hochrein, J. R. Engen, and T. E. Smithgall (2006)
J. Biol. Chem. 281, 30907-30916
 |  Abstract »  |  Full Text »  |  PDF »

The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.

F. Michor, Y. Iwasa, and M. A. Nowak (2006)
PNAS 103, 14931-14934
 |  Abstract »  |  Full Text »  |  PDF »

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP{alpha}.

G. Ferrari-Amorotti, K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti, S. Cattelani, N. J. Donato, and B. Calabretta (2006)
Blood 108, 1353-1362
 |  Abstract »  |  Full Text »  |  PDF »

Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib..

I. J. Griswold, M. MacPartlin, T. Bumm, V. L. Goss, T. O'Hare, K. A. Lee, A. S. Corbin, E. P. Stoffregen, C. Smith, K. Johnson, et al. (2006)
Mol. Cell. Biol. 26, 6082-6093
 |  Abstract »  |  Full Text »  |  PDF »

Mouse genomic representational oligonucleotide microarray analysis: Detection of copy number variations in normal and tumor specimens.

B. Lakshmi, I. M. Hall, C. Egan, J. Alexander, A. Leotta, J. Healy, L. Zender, M. S. Spector, W. Xue, S. W. Lowe, et al. (2006)
PNAS 103, 11234-11239
 |  Abstract »  |  Full Text »  |  PDF »

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

D. L. White, V. A. Saunders, P. Dang, J. Engler, A. C. W. Zannettino, A. C. Cambareri, S. R. Quinn, P. W. Manley, and T. P. Hughes (2006)
Blood 108, 697-704
 |  Abstract »  |  Full Text »  |  PDF »

Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide-Dependent Cellular Responses..

N. Giafis, E. Katsoulidis, A. Sassano, M. S. Tallman, L. S. Higgins, A. R. Nebreda, R. J. Davis, and L. C. Platanias (2006)
Cancer Res. 66, 6763-6771
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Myeloid Leukemia: Diagnosis and Treatment.

A. Quintas-Cardama and J. E. Cortes (2006)
Mayo Clin. Proc. 81, 973-988
 |  Abstract »  |  Full Text »  |  PDF »

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias..

M. Talpaz, N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'Brien, C. Nicaise, E. Bleickardt, et al. (2006)
N. Engl. J. Med. 354, 2531-2541
 |  Abstract »  |  Full Text »  |  PDF »

STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

D. Ye, N. Wolff, L. Li, S. Zhang, and R. L. Ilaria Jr (2006)
Blood 107, 4917-4925
 |  Abstract »  |  Full Text »  |  PDF »

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants.

J. S. Tokarski, J. A. Newitt, C. Y. J. Chang, J. D. Cheng, M. Wittekind, S. E. Kiefer, K. Kish, F. Y.F. Lee, R. Borzillerri, L. J. Lombardo, et al. (2006)
Cancer Res. 66, 5790-5797
 |  Abstract »  |  Full Text »  |  PDF »

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake (2006)
Blood 107, 4532-4539
 |  Abstract »  |  Full Text »  |  PDF »

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Y. Yamada, M. E. Rothenberg, A. W. Lee, H. S. Akei, E. B. Brandt, D. A. Williams, and J. A. Cancelas (2006)
Blood 107, 4071-4079
 |  Abstract »  |  Full Text »  |  PDF »

Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.

C. Guerzoni, M. Bardini, S. A. Mariani, G. Ferrari-Amorotti, P. Neviani, M. L. Panno, Y. Zhang, R. Martinez, D. Perrotti, and B. Calabretta (2006)
Blood 107, 4080-4089
 |  Abstract »  |  Full Text »  |  PDF »

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders.

R. L. Levine and G. Wernig (2006)
Hematology 2006, 233-239
 |  Abstract »  |  Full Text »  |  PDF »

Pathogenesis of Myelofibrosis With Myeloid Metaplasia.

A. Tefferi (2005)
J. Clin. Oncol. 23, 8520-8530
 |  Abstract »  |  Full Text »  |  PDF »

Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.

R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, Z. He, Y. Liang, Q. Lu, Y. Fang, X. Gan, et al. (2005)
Blood 106, 3142-3149
 |  Abstract »  |  Full Text »  |  PDF »

Differential regulation of the p70 S6 kinase pathway by interferon {alpha} (IFN{alpha}) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

S. Parmar, J. Smith, A. Sassano, S. Uddin, E. Katsoulidis, B. Majchrzak, S. Kambhampati, E. A. Eklund, M. S. Tallman, E. N. Fish, et al. (2005)
Blood 106, 2436-2443
 |  Abstract »  |  Full Text »  |  PDF »

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

D. White, V. Saunders, A. B. Lyons, S. Branford, A. Grigg, L. B. To, and T. Hughes (2005)
Blood 106, 2520-2526
 |  Abstract »  |  Full Text »  |  PDF »

Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.

F. B. Hickey, K. England, and T. G. Cotter (2005)
J. Leukoc. Biol. 78, 289-300
 |  Abstract »  |  Full Text »  |  PDF »

The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis.

A. Tefferi and D. G. Gilliland (2005)
Mayo Clin. Proc. 80, 947-958
 |  Abstract »  |  PDF »

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr (2005)
Blood 105, 3995-4003
 |  Abstract »  |  Full Text »  |  PDF »

BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells.

E. J. Andreu, E. Lledo, E. Poch, C. Ivorra, M. P. Albero, J. A. Martinez-Climent, C. Montiel-Duarte, J. Rifon, J. Perez-Calvo, C. Arbona, et al. (2005)
Cancer Res. 65, 3264-3272
 |  Abstract »  |  Full Text »  |  PDF »

p210BCR-ABL inhibits SDF-1 Chemotactic Response via Alteration of CXCR4 Signaling and Down-regulation of CXCR4 Expression.

J.-F. Geay, D. Buet, Y. Zhang, A. Foudi, P. Jarrier, M. Berthebaud, A. G. Turhan, W. Vainchenker, and F. Louache (2005)
Cancer Res. 65, 2676-2683
 |  Abstract »  |  Full Text »  |  PDF »

The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

M. Deininger, E. Buchdunger, and B. J. Druker (2005)
Blood 105, 2640-2653
 |  Abstract »  |  Full Text »  |  PDF »

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al. (2005)
Blood 105, 2281-2286
 |  Abstract »  |  Full Text »  |  PDF »

Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment.

A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian (2005)
Mayo Clin. Proc. 80, 390-402
 |  Abstract »  |  PDF »

Punish the parent not the progeny.

L. J. Elrick, H. G. Jorgensen, J. C. Mountford, and T. L. Holyoake (2005)
Blood 105, 1862-1866
 |  Abstract »  |  Full Text »  |  PDF »

Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.

Y. Zeng, M. W. Graner, S. Thompson, M. Marron, and E. Katsanis (2005)
Blood 105, 2016-2022
 |  Abstract »  |  Full Text »  |  PDF »

Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.

T. Maeda, F. Yagasaki, M. Ishikawa, N. Takahashi, and M. Bessho (2005)
Blood 105, 2115-2123
 |  Abstract »  |  Full Text »  |  PDF »

CD34+CD7+ Leukemic Progenitor Cells May Be Involved in Maintenance and Clonal Evolution of Chronic Myeloid Leukemia.

N. Kosugi, Y. Ebihara, T. Nakahata, H. Saisho, S. Asano, and A. Tojo (2005)
Clin. Cancer Res. 11, 505-511
 |  Abstract »  |  Full Text »  |  PDF »

Modeling CML in mice: SpeCiaL expression is the key.

R. A. Van Etten (2005)
Blood 105, 6-7
 |  Full Text »  |  PDF »

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

S. Koschmieder, B. Gottgens, P. Zhang, J. Iwasaki-Arai, K. Akashi, J. L. Kutok, T. Dayaram, K. Geary, A. R. Green, D. G. Tenen, et al. (2005)
Blood 105, 324-334
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive immunotherapy of murine CML: navigating between Scylla and Charybdis.

M. W. N. Deininger (2004)
Blood 104, 3843
 |  Full Text »  |  PDF »

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

K. W. H. Yee, M. Schittenhelm, A.-M. O'Farrell, A. R. Town, L. McGreevey, T. Bainbridge, J. M. Cherrington, and M. C. Heinrich (2004)
Blood 104, 4202-4209
 |  Abstract »  |  Full Text »  |  PDF »

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

M. A. Champagne, R. Capdeville, M. Krailo, W. Qu, B. Peng, M. Rosamilia, M. Therrien, U. Zoellner, S. M. Blaney, and M. Bernstein (2004)
Blood 104, 2655-2660
 |  Abstract »  |  Full Text »  |  PDF »

Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.

G. Bandyopadhyay, T. Biswas, K. C. Roy, S. Mandal, C. Mandal, B. C. Pal, S. Bhattacharya, S. Rakshit, D. K. Bhattacharya, U. Chaudhuri, et al. (2004)
Blood 104, 2514-2522
 |  Abstract »  |  Full Text »  |  PDF »

A Truncated Isoform of c-Mpl with an Essential C-terminal Peptide Targets the Full-length Receptor for Degradation.

J. Coers, C. Ranft, and R. C. Skoda (2004)
J. Biol. Chem. 279, 36397-36404
 |  Abstract »  |  Full Text »  |  PDF »

Genomic Mechanisms of p210BCR-ABL Signaling: INDUCTION OF HEAT SHOCK PROTEIN 70 THROUGH THE GATA RESPONSE ELEMENT CONFERS RESISTANCE TO PACLITAXEL-INDUCED APOPTOSIS.

S. Ray, Y. Lu, S. H. Kaufmann, W. C. Gustafson, J. E. Karp, I. Boldogh, A. P. Fields, and A. R. Brasier (2004)
J. Biol. Chem. 279, 35604-35615
 |  Abstract »  |  Full Text »  |  PDF »

A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2.

Y. Dai, M. Rahmani, S. J. Corey, P. Dent, and S. Grant (2004)
J. Biol. Chem. 279, 34227-34239
 |  Abstract »  |  Full Text »  |  PDF »

Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML.

C. H.M. Jamieson, L. E. Ailles, S. J. Dylla, M. Muijtjens, C. Jones, J. L. Zehnder, J. Gotlib, K. Li, M. G. Manz, A. Keating, et al. (2004)
N. Engl. J. Med. 351, 657-667
 |  Abstract »  |  Full Text »  |  PDF »

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al. (2004)
Blood 103, 4396-4407
 |  Abstract »  |  Full Text »  |  PDF »

Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells.

S. Parmar, E. Katsoulidis, A. Verma, Y. Li, A. Sassano, L. Lal, B. Majchrzak, F. Ravandi, M. S. Tallman, E. N. Fish, et al. (2004)
J. Biol. Chem. 279, 25345-25352
 |  Abstract »  |  Full Text »  |  PDF »

Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach.

R. M. Stone (2004)
Oncologist 9, 259-270
 |  Abstract »  |  Full Text »  |  PDF »

The biology of CML blast crisis.

B. Calabretta and D. Perrotti (2004)
Blood 103, 4010-4022
 |  Abstract »  |  Full Text »  |  PDF »

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

D. T. Le, N. Kong, Y. Zhu, J. O. Lauchle, A. Aiyigari, B. S. Braun, E. Wang, S. C. Kogan, M. M. Le Beau, L. Parada, et al. (2004)
Blood 103, 4243-4250
 |  Abstract »  |  Full Text »  |  PDF »

Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.

C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik (2004)
Blood 103, 4353-4361
 |  Abstract »  |  Full Text »  |  PDF »

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib.

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, et al. (2004)
N. Engl. J. Med. 350, 2129-2139
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of cell migration and survival by focal adhesion targeting of Lasp-1.

Y. H. Lin, Z.-Y. Park, D. Lin, A. A. Brahmbhatt, M.-C. Rio, J. R. Yates III, and R. L. Klemke (2004)
J. Cell Biol. 165, 421-432
 |  Abstract »  |  Full Text »  |  PDF »

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

A. Burchert, D. Cai, L. C. Hofbauer, M. K. R. Samuelsson, E. P. Slater, J. Duyster, M. Ritter, A. Hochhaus, R. Muller, M. Eilers, et al. (2004)
Blood 103, 3480-3489
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Stem Cells: Are We Missing the Target?.

R. J. Jones, W. H. Matsui, and B. D. Smith (2004)
J Natl Cancer Inst 96, 583-585
 |  Full Text »  |  PDF »

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

S. Chu, M. Holtz, M. Gupta, and R. Bhatia (2004)
Blood 103, 3167-3174
 |  Abstract »  |  Full Text »  |  PDF »

Bcr-Abl Regulates Protein Kinase C{iota} (PKC{iota}) Transcription via an Elk1 Site in the PKC{iota} Promoter.

W. C. Gustafson, S. Ray, L. Jamieson, E. A. Thompson, A. R. Brasier, and A. P. Fields (2004)
J. Biol. Chem. 279, 9400-9408
 |  Abstract »  |  Full Text »  |  PDF »

Coregulator-dependent facilitation of chromatin occupancy by GATA-1.

S. Pal, A. B. Cantor, K. D. Johnson, T. B. Moran, M. E. Boyer, S. H. Orkin, and E. H. Bresnick (2004)
PNAS 101, 980-985
 |  Abstract »  |  Full Text »  |  PDF »

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia.

N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. Aggarwal, S. Shishodin, M. Albitar, K. Hayes, H. Kantarjian, et al. (2004)
Cancer Res. 64, 672-677
 |  Abstract »  |  Full Text »  |  PDF »

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.

M. E. O'Dwyer, M. J. Mauro, C. Blasdel, M. Farnsworth, G. Kurilik, Y.-C. Hsieh, M. Mori, and B. J. Druker (2004)
Blood 103, 451-455
 |  Abstract »  |  Full Text »  |  PDF »

The Molecular Basis of Leukemia.

D. G. Gilliland, C. T. Jordan, and C. A. Felix (2004)
Hematology 2004, 80-97
 |  Abstract »  |  Full Text »  |  PDF »

FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.

G. Guasch, B. Delaval, C. Arnoulet, M.-J. Xie, L. Xerri, D. Sainty, D. Birnbaum, and M.-J. Pebusque (2004)
Blood 103, 309-312
 |  Abstract »  |  Full Text »  |  PDF »

Imatinib As a Paradigm of Targeted Therapies.

B. J. Druker (2003)
J. Clin. Oncol. 21, 239s-245
 |  Full Text »  |  PDF »

CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports.

E. Abruzzese, M. Cantonetti, L. Morino, G. Orlandi, A. Tendas, M.I. Del Principe, M. Masi, S. Amadori, A. Orlandi, L. Anemona, et al. (2003)
J. Clin. Oncol. 21, 4256-4258
 |  Full Text »  |  PDF »

To Advertise   |   Find Products